Portfolio news Archives

08.2020

Ventac Partners portfolio company RhoVac announced it has doses the first patient in its US clinical phase IIb trial, see press release here.

by Ventac Partners

06.2020

Ventac Partners portfolio company RhoVac announced it has received approval in Sweden to start its clinical phase IIb trial, see press release here.

by Ventac Partners

Ventac Partners announces the launch of Ambulero, a Miami-based spin-out of the University of Miami Miller Medical School focused on new gene and cell therapy approaches for treating vascular disease. For more information please visit www.ambulero.com.

by Ventac Partners

01.2020

Ventac Partners portfolio company Idogen announced that the company’s technology platform for tolerogenic dendritic cell generation has been successfully advanced from pilot to production-scale. For more information please follow this link.

by Ventac Partners

11.2019

Ventac Partners portfolio company RhoVac announced that the first patient has been screened for the company's clinical phase IIb study in prostate cancer, a study entitled RhoVac-002 ("BRaVac"). For more information please follow this link.

by Ventac Partners

08.2019

Ventac Partners portfolio company RhoVac reports it has been granted 2.5 million euro from Horizon 2020. For more information, please follow this link.

by Ventac Partners

06.2019

Ventac Partners portfolio company Idogen reports it has successfully established a novel method for the company's cell therapy. For more information, please follow this link.

by Ventac Partners

06.2019

Ventac Partners portfolio company RhoVac AB receives approval to start clinical phase IIb study in Denmark. For more information, please follow this link.

by Ventac Partners

07.2019

Ventac Partners portfolio company RhoVac reports positive results from the 12 months follow-up of the company’s phase I/II clinical study. For more information, please follow this link.

by Ventac Partners

04.2019

Ventac Partners portfolio company RhoVac announces that all patients completed the follow-up phase of the clinical phase I / II study. For more information, please follow this link.

by Ventac Partners